Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name CEND-1
Trade Name
Drug Descriptions

CEND-1 is a peptide that is targeted to tumors via interaction with alpha-integrins and potentially increases the delivery of other antitumor agents via interaction with neuropilin-1 (Annals of Oncology 31 (2020): S941).

CAS Registry Number 1392278-76-0
NCIT ID C103858


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
CEND-1 CEND-1 0 1
CEND-1 + Cisplatin + Durvalumab + Gemcitabine CEND-1 Cisplatin Durvalumab Gemcitabine 0 1
CEND-1 + Docetaxel CEND-1 Docetaxel 0 1
CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 Fluorouracil Irinotecan Leucovorin Oxaliplatin 0 1
CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab CEND-1 Fluorouracil Irinotecan Leucovorin Oxaliplatin Panitumumab 0 1
CEND-1 + Gemcitabine + Nab-paclitaxel CEND-1 Gemcitabine Nab-paclitaxel 0 1
CEND-1 + Paclitaxel CEND-1 Paclitaxel 0 1

Additional content available in CKB BOOST